Xencor’s Phase II trial of XmAb5871 for systemic erythematosus lupus (SLE) has a plethora of clinical trial design limitations that may...
Read More...
The post Xencor’s lupus drug evokes tepid expert response in Phase II study appeared first on Pharmaceutical Technology.
Original Article: Xencor’s lupus drug evokes tepid expert response in Phase II study